AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022

-Participants with SR-aGVHD disease achieved an ORR of 67% and CR of 17% as measured by best response-

-Participants with TR-aGVHD (11 of 12 concomitant ruxolitinib) achieved an ORR of 67% and CR of 25% at Day 28-

-Median survival benefits in TR-aGVHD participants compare favorably to historical controls
neihulizumab was well tolerated, with similar safety profiles observed when given alone or in combination with ruxolitinib-

Excerpt from the Press Release:

SAN FRANCISCO, Dec. 10, 2022 (GLOBE NEWSWIRE) — AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced the presentation of new data from its completed Phase 1b clinical trial evaluating ALTB-168 in patients with steroid-refractory (SR-aGVHD) or treatment-refractory (TR-aGVHD) acute graft-versus-host-disease at the 64^th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, La. The data will be presented in a poster by clinical trial investigator, Sameem Abedin, M.D., Assistant Professor, Medical College of Wisconsin, Cancer Center, Froedtert Hospital Medical.

“The promising efficacy, positive safety and tolerability of ALTB-168 is highly encouraging especially in this patient population that has minimal treatment options,” said Dr. Sameem Abedin, M.D., Assistant Professor, Medical College of Wisconsin, Cancer Center, Froedtert Hospital Medical, and a principal investigator participating in the clinical trial. “60% of patients with aGVHD do not respond to corticosteroids as first line treatment, and those that do not respond to any treatment have extremely poor outcomes. There is an urgent need to provide effective and long-lasting treatment options with less side effects.”

Jesse Hall, M.D., Chief Medical Officer of AltruBio added, “We’re pleased to share efficacy data demonstrating that treatment with an immune checkpoint enhancer, ALTB-168, has the potential to improve outcomes in patients with aGVHD. The clinical results in this indication validated the strategy of targeting PSGL-1 to control chronically active T cell-related immunological disorders and restore immune balance.

Click the button below to read the entire Press Release:

Continue Reading The Press Release